Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting

<p xmlns=”https://www.w3.org/1999/xhtml”><span class=”xn-location”>PEABODY, Mass., <span class=”xn-chron”>June 3, 2021 /PRNewswire/ — Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today a poster presentation on the safety…